Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 82 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,101,990 | -22.8% | 202,200 | -3.8% | 0.00% | -25.0% |
| Q2 2023 | $1,427,258 | +36.2% | 210,200 | +0.5% | 0.00% | +33.3% |
| Q1 2023 | $1,048,092 | +224.9% | 209,200 | +216.5% | 0.00% | +200.0% |
| Q4 2022 | $322,568 | +144.4% | 66,100 | +495.5% | 0.00% | – |
| Q1 2022 | $132,000 | -66.7% | 11,100 | -54.5% | 0.00% | -100.0% |
| Q4 2021 | $396,000 | -71.7% | 24,400 | -50.2% | 0.00% | -75.0% |
| Q3 2021 | $1,398,000 | -69.4% | 49,000 | -63.8% | 0.00% | -66.7% |
| Q2 2021 | $4,573,000 | -37.0% | 135,300 | -43.6% | 0.01% | -40.0% |
| Q1 2021 | $7,261,000 | +29.5% | 240,100 | +112.1% | 0.02% | +33.3% |
| Q4 2020 | $5,605,000 | +44.7% | 113,200 | +12.2% | 0.02% | +36.4% |
| Q3 2020 | $3,874,000 | +13.1% | 100,900 | +27.2% | 0.01% | +10.0% |
| Q2 2020 | $3,426,000 | +103.8% | 79,300 | +23.1% | 0.01% | +66.7% |
| Q1 2020 | $1,681,000 | +24.2% | 64,400 | +48.7% | 0.01% | +100.0% |
| Q4 2019 | $1,353,000 | – | 43,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |